;PMID: 9311623
;source_file_928.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..216] = [t:48..216]
;2)section:[e:220..265] = [t:220..265]
;3)section:[e:269..344] = [t:269..344]
;4)sentence:[e:348..419] = [t:348..419]
;5)sentence:[e:420..481] = [t:420..481]
;6)sentence:[e:482..646] = [t:482..646]
;7)sentence:[e:647..737] = [t:647..737]
;8)sentence:[e:738..1007] = [t:738..1007]
;9)sentence:[e:1008..1098] = [t:1008..1098]
;10)sentence:[e:1099..1200] = [t:1099..1200]
;11)sentence:[e:1201..1321] = [t:1201..1321]
;12)sentence:[e:1322..1437] = [t:1322..1437]
;13)sentence:[e:1438..1716] = [t:1438..1716]
;14)sentence:[e:1717..1871] = [t:1717..1871]
;15)sentence:[e:1872..1981] = [t:1872..1981]
;16)sentence:[e:1982..2128] = [t:1982..2128]
;17)sentence:[e:2129..2320] = [t:2129..2320]
;18)sentence:[e:2321..2500] = [t:2321..2500]
;19)sentence:[e:2501..2637] = [t:2501..2637]
;20)sentence:[e:2638..2826] = [t:2638..2826]
;21)section:[e:2830..2874] = [t:2830..2874]

;section 0 Span:0..42
;Drug Metab Dispos. 1997 Sep;25(9):1072-80.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) (CD:[19..23] 1997) (CC:[24..31] Sep;25-LRB-)
        (CD:[31..32] 9) (-RRB-:[32..33] -RRB-) (CD:[33..38] :1072)
        (::[38..39] -) (CD:[39..41] 80) (.:[41..42] .)))

;sentence 1 Span:48..216
;Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: 
;implications for interindividual variability in disposition, efficacy, and
;drug  interactions.
;[48..56]:substance:"Fentanyl"
;[100..119]:cyp450:"cytochrome P450 3A4"
;[197..201]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[48..56] Fentanyl) (NN:[57..67] metabolism))
      (PP (IN:[68..70] by)
        (NP
          (NP
            (ADJP-2 (JJ:[71..76] human))
            (JJ:[77..84] hepatic)
            (NML-1 (-NONE-:[84..84] *P*)))
          (CC:[85..88] and)
          (NP
            (ADJP-2 (-NONE-:[88..88] *P*))
            (JJ:[89..99] intestinal)
            (NML-1
              (NML (NN:[100..110] cytochrome) (NN:[111..115] P450))
              (NN:[116..119] 3A4))))))
    (::[119..120] :)
    (NP
      (NP (NNS:[122..134] implications))
      (PP (IN:[135..138] for)
        (NP
          (NP (JJ:[139..154] interindividual) (NN:[155..166] variability))
          (PP-LOC (IN:[167..169] in)
            (NP
              (NP (NN:[170..181] disposition))
              (,:[181..182] ,)
              (NP (NN:[183..191] efficacy))
              (,:[191..192] ,) (CC:[193..196] and)
              (NP (NN:[197..201] drug) (NNS:[203..215] interactions)))))))
    (.:[215..216] .)))

;section 2 Span:220..265
;Labroo RB, Paine MF, Thummel KE, Kharasch ED.
(SEC
  (FRAG (NNP:[220..226] Labroo) (NN:[227..229] RB) (,:[229..230] ,)
        (NNP:[231..236] Paine) (NNP:[237..239] MF) (,:[239..240] ,)
        (NNP:[241..248] Thummel) (NNP:[249..251] KE) (,:[251..252] ,)
        (NNP:[253..261] Kharasch) (NNP:[262..264] ED) (.:[264..265] .)))

;section 3 Span:269..344
;Department of Anesthesiology, University of Washington, Seattle 98195, USA.
(SEC
  (FRAG (NNP:[269..279] Department) (IN:[280..282] of)
        (NNP:[283..297] Anesthesiology) (,:[297..298] ,)
        (NNP:[299..309] University) (IN:[310..312] of)
        (NNP:[313..323] Washington) (,:[323..324] ,) (NNP:[325..332] Seattle)
        (CD:[333..338] 98195) (,:[338..339] ,) (NNP:[340..343] USA)
        (.:[343..344] .)))

;sentence 4 Span:348..419
;The synthetic opioid fentanyl undergoes extensive metabolism in humans.
;[362..368]:substance:"opioid"
;[369..377]:substance:"fentanyl"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[348..351] The) (JJ:[352..361] synthetic) (JJ:[362..368] opioid))
      (NP (NN:[369..377] fentanyl)))
    (VP (VBZ:[378..387] undergoes)
      (NP (JJ:[388..397] extensive) (NN:[398..408] metabolism))
      (PP-LOC (IN:[409..411] in)
        (NP (NNS:[412..418] humans))))
    (.:[418..419] .)))

;sentence 5 Span:420..481
;Systemic  elimination occurs primarily by hepatic metabolism.
(SENT
  (S
    (NP-SBJ (JJ:[420..428] Systemic) (NN:[430..441] elimination))
    (VP (VBZ:[442..448] occurs)
      (ADVP (RB:[449..458] primarily))
      (PP-MNR (IN:[459..461] by)
        (NP (JJ:[462..469] hepatic) (NN:[470..480] metabolism))))
    (.:[480..481] .)))

;sentence 6 Span:482..646
;When administered as a  lozenge for oral transmucosal absorption, swallowed
;fentanyl is subject to first  pass metabolism in the liver and possibly small
;intestine.
;[506..513]:substance:"lozenge"
;[558..566]:substance:"fentanyl"
(SENT
  (S
    (SBAR-TMP
      (WHADVP-3 (WRB:[482..486] When))
      (S
        (NP-SBJ-2 (-NONE-:[486..486] *))
        (VP (VBN:[487..499] administered)
          (NP-2 (-NONE-:[499..499] *))
          (PP (IN:[500..502] as)
            (NP
              (NP (DT:[503..504] a) (NN:[506..513] lozenge))
              (PP (IN:[514..517] for)
                (NP (JJ:[518..522] oral) (JJ:[523..535] transmucosal)
                    (NN:[536..546] absorption)))))
          (ADVP-TMP-3 (-NONE-:[546..546] *T*)))))
    (,:[546..547] ,)
    (NP-SBJ (VBN:[548..557] swallowed) (NN:[558..566] fentanyl))
    (VP (VBZ:[567..569] is)
      (ADJP-PRD (JJ:[570..577] subject)
        (PP (TO:[578..580] to)
          (NP
            (NP
              (NML (JJ:[581..586] first) (NN:[588..592] pass))
              (NN:[593..603] metabolism))
            (PP-LOC (IN:[604..606] in)
              (NP
                (NP (DT:[607..610] the) (NN:[611..616] liver))
                (CC:[617..620] and)
                (NP
                  (ADVP (RB:[621..629] possibly))
                  (JJ:[630..635] small) (NN:[636..645] intestine))))))))
    (.:[645..646] .)))

;sentence 7 Span:647..737
;Little is known,  however, about the identity and formation of human fentanyl
;metabolites.
;[716..736]:substance:"fentanyl metabolites"
(SENT
  (S
    (NP-SBJ-1 (JJ:[647..653] Little))
    (VP (VBZ:[654..656] is)
      (VP (VBN:[657..662] known)
        (NP-1 (-NONE-:[662..662] *))
        (,:[662..663] ,)
        (ADVP (RB:[665..672] however))
        (,:[672..673] ,)
        (PP (IN:[674..679] about)
          (NP
            (NP (DT:[680..683] the) (NN:[684..692] identity) (CC:[693..696] and)
                (NN:[697..706] formation))
            (PP (IN:[707..709] of)
              (NP (JJ:[710..715] human)
                 (NN:[716..724] fentanyl) (NNS:[725..736] metabolites)))))))
    (.:[736..737] .)))

;sentence 8 Span:738..1007
;This  investigation identified routes of human liver microsomal fentanyl
;metabolism  and their relative importance, tested the hypothesis that
;fentanyl is  metabolized by human duodenal microsomes, and identified the
;predominantly  responsible cytochrome P450 isoforms.
;[802..810]:substance:"fentanyl"
;[881..889]:substance:"fentanyl"
;[982..1006]:cyp450:"cytochrome P450 isoforms"
(SENT
  (S
    (NP-SBJ (DT:[738..742] This) (NN:[744..757] investigation))
    (VP
      (VP (VBD:[758..768] identified)
        (NP
          (NP
            (NP (NNS:[769..775] routes))
            (PP (IN:[776..778] of)
              (NP (JJ:[779..784] human) (NN:[785..790] liver)
                  (JJ:[791..801] microsomal) (NN:[802..810] fentanyl)
                  (NN:[811..821] metabolism))))
          (CC:[823..826] and)
          (NP (PRP$:[827..832] their) (JJ:[833..841] relative)
              (NN:[842..852] importance))))
      (,:[852..853] ,)
      (VP (VBD:[854..860] tested)
        (NP (DT:[861..864] the) (NN:[865..875] hypothesis)
          (SBAR (IN:[876..880] that)
            (S
              (NP-SBJ-1 (NN:[881..889] fentanyl))
              (VP (VBZ:[890..892] is)
                (VP (VBN:[894..905] metabolized)
                  (NP-1 (-NONE-:[905..905] *))
                  (PP (IN:[906..908] by)
                    (NP-LGS (JJ:[909..914] human) (JJ:[915..923] duodenal)
                            (NNS:[924..934] microsomes)))))))))
      (,:[934..935] ,) (CC:[936..939] and)
      (VP (VBD:[940..950] identified)
        (NP (DT:[951..954] the)
          (ADJP (RB:[955..968] predominantly) (JJ:[970..981] responsible))
          
          (NML (NN:[982..992] cytochrome) (NN:[993..997] P450))
          (NNS:[998..1006] isoforms))))
    (.:[1006..1007] .)))

;sentence 9 Span:1008..1098
;A GC/MS assay using deuterated internal  standards was developed for fentanyl
;metabolites.
;[1077..1097]:substance:"fentanyl metabolites"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1008..1009] A)
        (NML (NN:[1010..1012] GC) (SYM:[1012..1013] /) (NN:[1013..1015] MS))
        (NN:[1016..1021] assay))
      (VP (VBG:[1022..1027] using)
        (NP (VBN:[1028..1038] deuterated) (JJ:[1039..1047] internal)
            (NNS:[1049..1058] standards))))
    (VP (VBD:[1059..1062] was)
      (VP (VBN:[1063..1072] developed)
        (NP-1 (-NONE-:[1072..1072] *))
        (PP (IN:[1073..1076] for)
          (NP (NN:[1077..1085] fentanyl) (NNS:[1086..1097] metabolites)))))
    (.:[1097..1098] .)))

;sentence 10 Span:1099..1200
;Piperidine N-dealkylation to  norfentanyl was the predominant pathway of
;liver microsomal metabolism.
;[1099..1109]:substance:"Piperidine"
;[1129..1140]:substance:"norfentanyl"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1099..1109] Piperidine) (NN:[1110..1124] N-dealkylation))
      (PP (TO:[1125..1127] to)
        (NP (NN:[1129..1140] norfentanyl))))
    (VP (VBD:[1141..1144] was)
      (NP-PRD
        (NP (DT:[1145..1148] the) (JJ:[1149..1160] predominant)
            (NN:[1161..1168] pathway))
        (PP (IN:[1169..1171] of)
          (NP (NN:[1172..1177] liver) (JJ:[1178..1188] microsomal)
              (NN:[1189..1199] metabolism)))))
    (.:[1199..1200] .)))

;sentence 11 Span:1201..1321
;Amide  hydrolysis to despropionylfentanyl and alkyl hydroxylation to
;hydroxyfentanyl  were comparatively minor pathways.
;[1222..1242]:substance:"despropionylfentanyl"
;[1270..1285]:substance:"hydroxyfentanyl"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1201..1206] Amide) (NN:[1208..1218] hydrolysis))
        (PP (TO:[1219..1221] to)
          (NP (NN:[1222..1242] despropionylfentanyl))))
      (CC:[1243..1246] and)
      (NP
        (NP (NN:[1247..1252] alkyl) (NN:[1253..1266] hydroxylation))
        (PP (TO:[1267..1269] to)
          (NP (NN:[1270..1285] hydroxyfentanyl)))))
    (VP (VBD:[1287..1291] were)
      (NP-PRD
        (ADJP (RB:[1292..1305] comparatively) (JJ:[1306..1311] minor))
        (NNS:[1312..1320] pathways)))
    (.:[1320..1321] .)))

;sentence 12 Span:1322..1437
;Hydroxynorfentanyl was identified as a minor,  secondary metabolite arising
;from N-dealkylation of hydroxyfentanyl.
;[1322..1340]:substance:"Hydroxynorfentanyl"
;[1379..1389]:substance:"metabolite"
;[1421..1436]:substance:"hydroxyfentanyl"
(SENT
  (S
    (NP-SBJ-1 (NN:[1322..1340] Hydroxynorfentanyl))
    (VP (VBD:[1341..1344] was)
      (VP (VBN:[1345..1355] identified)
        (NP-1 (-NONE-:[1355..1355] *))
        (PP-CLR (IN:[1356..1358] as)
          (NP
            (NP (DT:[1359..1360] a) (JJ:[1361..1366] minor) (,:[1366..1367] ,)
                (JJ:[1369..1378] secondary) (NN:[1379..1389] metabolite))
            (VP (VBG:[1390..1397] arising)
              (PP-CLR (IN:[1398..1402] from)
                (NP
                  (NP (NN:[1403..1417] N-dealkylation))
                  (PP (IN:[1418..1420] of)
                    (NP (NN:[1421..1436] hydroxyfentanyl))))))))))
    (.:[1436..1437] .)))

;sentence 13 Span:1438..1716
;Liver  microsomal norfentanyl formation was significantly inhibited by the 
;mechanism-based P450 3A4 inhibitor troleandomycin and the P450 3A4 substrate
;and  competitive inhibitor midazolam, and was significantly correlated with
;P450 3A4  protein content and catalytic activity.
;[1456..1467]:substance:"norfentanyl"
;[1530..1538]:cyp450:"P450 3A4"
;[1539..1548]:substance:"inhibitor"
;[1549..1563]:substance:"troleandomycin"
;[1572..1580]:cyp450:"P450 3A4"
;[1581..1590]:substance:"substrate"
;[1608..1617]:substance:"inhibitor"
;[1618..1627]:substance:"midazolam"
;[1667..1684]:cyp450:"P450 3A4  protein"
(SENT
  (S
    (NP-SBJ-3 (NN:[1438..1443] Liver) (JJ:[1445..1455] microsomal)
              (NN:[1456..1467] norfentanyl) (NN:[1468..1477] formation))
    (VP
      (VP (VBD:[1478..1481] was)
        (ADVP-EXT (RB:[1482..1495] significantly))
        (VP (VBN:[1496..1505] inhibited)
          (NP-3 (-NONE-:[1505..1505] *))
          (PP (IN:[1506..1508] by)
            (NP-LGS
              (NP
                (NP (DT:[1509..1512] the)
                  (ADJP (NN:[1514..1523] mechanism) (HYPH:[1523..1524] -)
                        (VBN:[1524..1529] based))
                  (NML (NN:[1530..1534] P450) (NN:[1535..1538] 3A4))
                  (NN:[1539..1548] inhibitor))
                (NP (NN:[1549..1563] troleandomycin)))
              (CC:[1564..1567] and)
              (NP
                (NP (DT:[1568..1571] the)
                  (NML
                    (NML
                      (NML-2 (NN:[1572..1576] P450) (NN:[1577..1580] 3A4))
                      (NN:[1581..1590] substrate))
                    (CC:[1591..1594] and)
                    (NML
                      (NML-2 (-NONE-:[1594..1594] *P*))
                      (JJ:[1596..1607] competitive) (NN:[1608..1617] inhibitor))))
                (NP (NN:[1618..1627] midazolam)))))))
      (,:[1627..1628] ,) (CC:[1629..1632] and)
      (VP (VBD:[1633..1636] was)
        (ADVP-EXT (RB:[1637..1650] significantly))
        (VP (VBN:[1651..1661] correlated)
          (NP-3 (-NONE-:[1661..1661] *))
          (PP-CLR (IN:[1662..1666] with)
            (NP
              (NP
                
                (NML-1 (NN:[1667..1671] P450) (NN:[1672..1675] 3A4))
                (NN:[1677..1684] protein)
                (NN:[1685..1692] content))
              (CC:[1693..1696] and)
              (NP
                (NML-1 (-NONE-:[1696..1696] *P*))
                (JJ:[1697..1706] catalytic) (NN:[1707..1715] activity)))))))
    (.:[1715..1716] .)))

;sentence 14 Span:1717..1871
;Of six expressed human P450 isoforms  (P450s 1A2, 2B6, 2C9, 2D6, 2E1, and
;3A4), only P450 3A4 exhibited significant  fentanyl dealkylation to
;norfentanyl.
;[1740..1753]:cyp450:"P450 isoforms"
;[1756..1765]:cyp450:"P450s 1A2"
;[1756..1761]...[1791..1794]:cyp450:"P450s"..."3A4"
;[1756..1761]...[1782..1785]:cyp450:"P450s"..."2E1"
;[1756..1761]...[1777..1780]:cyp450:"P450s"..."2D6"
;[1756..1761]...[1772..1775]:cyp450:"P450s"..."2C9"
;[1756..1761]...[1767..1770]:cyp450:"P450s"..."2B6"
;[1802..1810]:cyp450:"P450 3A4"
;[1834..1842]:substance:"fentanyl"
;[1859..1870]:substance:"norfentanyl"
(SENT
  (S
    (PP (IN:[1717..1719] Of)
      (NP (CD:[1720..1723] six) (VBN:[1724..1733] expressed)
          (JJ:[1734..1739] human)
         (NN:[1740..1744] P450) (NNS:[1745..1753] isoforms)
        (PRN (-LRB-:[1755..1756] -LRB-)
          (NP
            (NP
              (NML-1 (NNS:[1756..1761] P450s))
              (NN:[1762..1765] 1A2))
            (,:[1765..1766] ,)
            (NP
              (NML-1 (-NONE-:[1766..1766] *P*))
              (NN:[1767..1770] 2B6))
            (,:[1770..1771] ,)
            (NP
              (NML-1 (-NONE-:[1771..1771] *P*))
              (NN:[1772..1775] 2C9))
            (,:[1775..1776] ,)
            (NP
              (NML-1 (-NONE-:[1776..1776] *P*))
              (NN:[1777..1780] 2D6))
            (,:[1780..1781] ,)
            (NP
              (NML-1 (-NONE-:[1781..1781] *P*))
              (NN:[1782..1785] 2E1))
            (,:[1785..1786] ,) (CC:[1787..1790] and)
            (NP
              (NML-1 (-NONE-:[1790..1790] *P*))
              (NN:[1791..1794] 3A4)))
          (-RRB-:[1794..1795] -RRB-))))
    (,:[1795..1796] ,)
    (NP-SBJ (RB:[1797..1801] only)
       (NN:[1802..1806] P450) (NN:[1807..1810] 3A4))
    (VP (VBD:[1811..1820] exhibited)
      (NP
        (NP (JJ:[1821..1832] significant) (NN:[1834..1842] fentanyl)
            (NN:[1843..1855] dealkylation))
        (PP (TO:[1856..1858] to)
          (NP (NN:[1859..1870] norfentanyl)))))
    (.:[1870..1871] .)))

;sentence 15 Span:1872..1981
;These results indicate the predominant  role of P450 3A4 in the primary route
;of hepatic fentanyl metabolism.
;[1920..1928]:cyp450:"P450 3A4"
;[1961..1969]:substance:"fentanyl"
(SENT
  (S
    (NP-SBJ (DT:[1872..1877] These) (NNS:[1878..1885] results))
    (VP (VBP:[1886..1894] indicate)
      (NP
        (NP (DT:[1895..1898] the) (JJ:[1899..1910] predominant)
            (NN:[1912..1916] role))
        (PP (IN:[1917..1919] of)
          (NP (NN:[1920..1924] P450) (NN:[1925..1928] 3A4))))
      (PP (IN:[1929..1931] in)
        (NP
          (NP (DT:[1932..1935] the) (JJ:[1936..1943] primary)
              (NN:[1944..1949] route))
          (PP (IN:[1950..1952] of)
            (NP (JJ:[1953..1960] hepatic) (NN:[1961..1969] fentanyl)
                (NN:[1970..1980] metabolism))))))
    (.:[1980..1981] .)))

;sentence 16 Span:1982..2128
;Human  duodenal microsomes also catalyzed fentanyl metabolism to norfentanyl;
;the  average rate was approximately half that of hepatic metabolism.
;[2024..2032]:substance:"fentanyl"
;[2047..2058]:substance:"norfentanyl"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[1982..1987] Human) (JJ:[1989..1997] duodenal)
              (NNS:[1998..2008] microsomes))
      (ADVP (RB:[2009..2013] also))
      (VP (VBD:[2014..2023] catalyzed)
        (NP
          (NP (NN:[2024..2032] fentanyl) (NN:[2033..2043] metabolism))
          (PP (TO:[2044..2046] to)
            (NP (NN:[2047..2058] norfentanyl))))))
    (::[2058..2059] ;)
    (S
      (NP-SBJ (DT:[2060..2063] the) (JJ:[2065..2072] average)
              (NN:[2073..2077] rate))
      (VP (VBD:[2078..2081] was)
        (NP-PRD
          (NP
            (QP (RB:[2082..2095] approximately) (RB:[2096..2100] half))
            (DT:[2101..2105] that))
          (PP (IN:[2106..2108] of)
            (NP (JJ:[2109..2116] hepatic) (NN:[2117..2127] metabolism))))))
    (.:[2127..2128] .)))

;sentence 17 Span:2129..2320
;Rates of  duodenal norfentanyl formation were diminished by troleandomycin
;and midazolam,  and were significantly correlated with P450 3A4 activity,
;suggesting a prominent  role for P450 3A4.
;[2148..2159]:substance:"norfentanyl"
;[2189..2203]:substance:"troleandomycin"
;[2208..2217]:substance:"midazolam"
;[2259..2267]:cyp450:"P450 3A4"
;[2311..2319]:cyp450:"P450 3A4"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[2129..2134] Rates))
      (PP (IN:[2135..2137] of)
        (NP (JJ:[2139..2147] duodenal) (NN:[2148..2159] norfentanyl)
            (NN:[2160..2169] formation))))
    (VP
      (VP (VBD:[2170..2174] were)
        (VP (VBN:[2175..2185] diminished)
          (NP-1 (-NONE-:[2185..2185] *))
          (PP (IN:[2186..2188] by)
            (NP-LGS (NN:[2189..2203] troleandomycin) (CC:[2204..2207] and)
                    (NN:[2208..2217] midazolam)))))
      (,:[2217..2218] ,) (CC:[2220..2223] and)
      (VP (VBD:[2224..2228] were)
        (ADVP (RB:[2229..2242] significantly))
        (VP (VBN:[2243..2253] correlated)
          (NP-1 (-NONE-:[2253..2253] *))
          (PP-CLR (IN:[2254..2258] with)
            (NP
              (NML (NN:[2259..2263] P450) (NN:[2264..2267] 3A4))
              (NN:[2268..2276] activity)))
          (,:[2276..2277] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[2277..2277] *))
            (VP (VBG:[2278..2288] suggesting)
              (NP
                (NP (DT:[2289..2290] a) (JJ:[2291..2300] prominent)
                    (NN:[2302..2306] role))
                (PP (IN:[2307..2310] for)
                  (NP (NN:[2311..2315] P450) (NN:[2316..2319] 3A4)))))))))
    (.:[2319..2320] .)))

;sentence 18 Span:2321..2500
;These results demonstrate that human intestinal as well as  liver microsomes
;catalyze fentanyl metabolism, and N-dealkylation by P450 3A4 is  the
;predominant route in both organs.
;[2407..2415]:substance:"fentanyl"
;[2450..2458]:cyp450:"P450 3A4"
(SENT
  (S
    (NP-SBJ (DT:[2321..2326] These) (NNS:[2327..2334] results))
    (VP (VBP:[2335..2346] demonstrate)
      (SBAR (IN:[2347..2351] that)
        (S
          (S
            (NP-SBJ
              (NP
                (ADJP-2 (JJ:[2352..2357] human))
                (JJ:[2358..2368] intestinal)
                (NML-1 (-NONE-:[2368..2368] *P*)))
              (CONJP (RB:[2369..2371] as) (RB:[2372..2376] well)
                     (IN:[2377..2379] as))
              (NP
                (ADJP-2 (-NONE-:[2379..2379] *P*))
                (NN:[2381..2386] liver)
                (NML-1 (NNS:[2387..2397] microsomes))))
            (VP (VBP:[2398..2406] catalyze)
              (NP (NN:[2407..2415] fentanyl) (NN:[2416..2426] metabolism))))
          (,:[2426..2427] ,) (CC:[2428..2431] and)
          (S
            (NP-SBJ
              (NP (NN:[2432..2446] N-dealkylation))
              (PP (IN:[2447..2449] by)
                (NP (NN:[2450..2454] P450) (NN:[2455..2458] 3A4))))
            (VP (VBZ:[2459..2461] is)
              (NP-PRD (DT:[2463..2466] the) (JJ:[2467..2478] predominant)
                      (NN:[2479..2484] route))
              (PP-LOC (IN:[2485..2487] in)
                (NP (DT:[2488..2492] both) (NNS:[2493..2499] organs))))))))
    (.:[2499..2500] .)))

;sentence 19 Span:2501..2637
;The fraction of fentanyl lozenge that is  swallowed likely undergoes
;significant intestinal, as well as hepatic,  first-pass metabolism.
;[2517..2533]:substance:"fentanyl lozenge"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[2501..2504] The) (NN:[2505..2513] fraction))
        (PP (IN:[2514..2516] of)
          (NP (NN:[2517..2525] fentanyl) (NN:[2526..2533] lozenge))))
      (SBAR
        (WHNP-4 (WDT:[2534..2538] that))
        (S
          (NP-SBJ-4 (-NONE-:[2538..2538] *T*))
          (VP (VBZ:[2539..2541] is)
            (VP (VBN:[2543..2552] swallowed)
              (NP-4 (-NONE-:[2552..2552] *)))))))
    (ADVP (RB:[2553..2559] likely))
    (VP (VBZ:[2560..2569] undergoes)
      (NP
        (NP
          (ADJP-3 (JJ:[2570..2581] significant))
          (JJ:[2582..2592] intestinal)
          (NML-1 (-NONE-:[2592..2592] *P*))
          (NML-2 (-NONE-:[2592..2592] *P*)))
        (,:[2592..2593] ,)
        (CONJP (RB:[2594..2596] as) (RB:[2597..2601] well) (IN:[2602..2604] as))
        (NP
          (ADJP-3 (-NONE-:[2604..2604] *P*))
          (JJ:[2605..2612] hepatic) (,:[2612..2613] ,)
          (NML-1 (JJ:[2615..2620] first) (HYPH:[2620..2621] -)
                 (NN:[2621..2625] pass))
          (NML-2 (NN:[2626..2636] metabolism)))))
    (.:[2636..2637] .)))

;sentence 20 Span:2638..2826
;Intestinal and hepatic first-pass metabolism, as well as  systemic
;metabolism, may be subject to individual variability in P450 3A4  expression
;and to drug interactions involving P450 3A4.
;[2761..2769]:cyp450:"P450 3A4"
;[2789..2793]:substance:"drug"
;[2817..2825]:cyp450:"P450 3A4"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[2638..2648] Intestinal)
          (NML-1 (-NONE-:[2648..2648] *P*))
          (NML-2 (-NONE-:[2648..2648] *P*)))
        (CC:[2649..2652] and)
        (NP (JJ:[2653..2660] hepatic)
          (NML-1 (JJ:[2661..2666] first) (HYPH:[2666..2667] -)
                 (NN:[2667..2671] pass))
          (NML-2 (NN:[2672..2682] metabolism))))
      (,:[2682..2683] ,)
      (CONJP (RB:[2684..2686] as) (RB:[2687..2691] well) (IN:[2692..2694] as))
      (NP (JJ:[2696..2704] systemic) (NN:[2705..2715] metabolism)))
    (,:[2715..2716] ,)
    (VP (MD:[2717..2720] may)
      (VP (VB:[2721..2723] be)
        (ADJP-PRD (JJ:[2724..2731] subject)
          (PP
            (PP (TO:[2732..2734] to)
              (NP
                (NP (JJ:[2735..2745] individual) (NN:[2746..2757] variability))
                (PP (IN:[2758..2760] in)
                  (NP
                    (NML (NN:[2761..2765] P450) (NN:[2766..2769] 3A4))
                    (NN:[2771..2781] expression)))))
            (CC:[2782..2785] and)
            (PP (TO:[2786..2788] to)
              (NP
                (NP (NN:[2789..2793] drug) (NNS:[2794..2806] interactions))
                (VP (VBG:[2807..2816] involving)
                  (NP (NN:[2817..2821] P450) (NN:[2822..2825] 3A4)))))))))
    (.:[2825..2826] .)))

;section 21 Span:2830..2874
;PMID: 9311623 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2830..2834] PMID) (::[2834..2835] :) (CD:[2836..2843] 9311623)
        (NN:[2844..2845] -LSB-) (NNP:[2845..2851] PubMed) (::[2852..2853] -)
        (NN:[2854..2861] indexed) (IN:[2862..2865] for)
        (NNP:[2866..2874] MEDLINE-RSB-)))
